TrialHIV medicine2025

DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.

Joana Woods et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.